Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Partners4Access

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Research Partnership

- PMLiVE

SMC decides Celgene’s Imnovid is not cost-effective

Scottish cancer patients denied access to the cancer drug

UK flag

Pharma industry backs UK antibiotics plan

GSK and ABPI back David Cameron’s call for global action on antimicrobial resistance

EU flag

Updated EMA reports better suited to HTA needs

Changes to drug licensing reports are helping to support reimbursement decisions

UK flag

Lilly invests in UK life sciences via biotech fund

Will support work of UK universities

- PMLiVE

Oxford PharmaGenesis launches its new HealthScience approach

Unveils integrated approach to engaging physicians, patients and policy-makers

- PMLiVE

UK pharma’s ‘controversial’ new pharmacist compliance rules

As the changes take effect CompliMed's Dr Rina Newton says they look to be a practical step forward

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

- PMLiVE

ABPI appoints value and access manager

Christine Rowland joins from Pfizer

- PMLiVE

NICE won’t back early use of Zytiga in prostate cancer

Says Janssen drug should not be used prior to chemotherapy

Oncology drugs under AMNOG: part one

Segmentation and comparator choice - lessons for cancer drug market access in Germany

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links